Legal Representation
Attorney
Ann K. Ford
USPTO Deadlines
Application History
8 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 5, 2019 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Sep 5, 2019 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Feb 7, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 31, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 3, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 26, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Immunotherapeutic agents, namely, antibodies, vaccines, and pharmaceutical preparations thereof for the treatment of cancer and neurodegenerative, neurodevelopmental and cognitive disorders; Therapeutic agents for transport and delivery of small molecules and biologics to the lymphatic system; Exosome-based pharmaceutical preparations to facilitate the oral administration and delivery of therapeutic agents; pharmaceutical preparations for the modulation of lymphatic function in the brain for the treatment, prevention, and delayed onset of central nervous system disorders, Alzheimer's disease, Huntington's disease, age-associated cognitive decline and diseases associated with neurodegenerative, neurodevelopmental and cognitive disorders; Therapeutic agents for the treatment of fibrotic diseases, namely, interstitial lung disease, pulmonary fibrosis, lymphedema, sclerosis, and scleroderma
Classification
International Classes
005